AAFPRS President Addresses Concerns About Moderna COVID-19 Vaccine
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.